Acute Plasmodium yoelii 17XNL Infection During BCG Vaccination Limits T Cell Responses and Mycobacterial Growth Inhibition.
Tangie E. et al, (2025), Immunology
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Marshall JL. et al, (2025), Nature Communications, 16
Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review
Torracinta L. et al, (2025), Frontiers in Immunology, 16
Workshop report: One Health challenges and knowledge gaps in the control of intracellular infections with a focus on tuberculosis and leishmaniasis
Miller M. et al, (2025), Vaccine, 53, 126929 - 126929
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Determinants of COVID-19 immunisation uptake in a country with high mortality and a low vaccination rate
Aksentijevic D. et al, (2023), Journal of Infection and Public Health, 16, 1322 - 1331
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Satti I. et al, (2022), Nature Communications, 13
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
Yeo T. et al, (2022), Journal of Neuroinflammation, 19
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Wilkie M. et al, (2022), Scientific reports, 12
Chronovaccination: Harnessing circadian rhythms to optimize immunisation strategies.
Otasowie CO. et al, (2022), Frontiers in immunology, 13
Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.
Burel JG. et al, (2021), Tuberculosis (Edinburgh, Scotland), 131
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
MMR Vaccine Attitude and Uptake Research in the United Kingdom: A Critical Review
Torracinta L. et al, (2021), Vaccines, 9, 402 - 402
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891